Heartworm Treatment Products Market Companies and Growth
- Zoetis Inc.
- Elanco Animal Health
- Boehringer Ingelheim Animal Health
- Merck Animal Health
- Ceva Santé Animale
- Virbac SA
- Vetoquinol SA
- Dechra Pharmaceuticals
- Bayer Animal Health
- Bimeda Inc.
- Norbrook Laboratories
- Chanelle Pharma
- Krka Animal Health
- SavaVet (Sava Healthcare)
- Pharmgate Animal Health
- Zydus Animal Health
- Aurora Pharmaceuticals
- Aratana Therapeutics
- Kyoritsu Seiyaku
- Provet Pharma
Market Growth
The global heartworm treatment products market size is calculated at US$ 1.45 billion in 2024, grew to US$ 1.55 billion in 2025, and is projected to reach around US$ 2.85 billion by 2034. The market is expanding at a CAGR of 7.04% between 2025 and 2034.
What are the Trends in the Heartworm Treatment Products Market?
- The market is expanding due to the increasing strategic initiatives from manufacturers to accelerate their product portfolios.
- In August 2025, Zomedica Corp., a veterinary health company, partnered with VerticalVet, one of the veterinary industry's most respected Group Purchasing Organizations (GPOs), supporting over 2,600 independent veterinary practices around the United States.
- In May 2025, Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, invested $895 million in Merck Animal Health’s manufacturing facility and R&D facilities in De Soto, Kansas.
The Market Value Chain Analysis
R&D
This mainly includes the discovery of potential active compounds, formulation development, robust clinical and laboratory testing to evaluate efficiency and safety for target species (dogs, cats, ferrets), and finally, regulatory approval and post-market surveillance, with ultimate guidance from organizations, especially the FDA and the American Heartworm Society.
Key Players: Merck Animal Health, Zoetis, Virbac, etc.
Distribution to Hospitals, Pharmacies
The heartworm treatment products market encompasses the distribution through manufacturers who are delivering drugs to licensed wholesalers and distributors, who then supply them to specialized veterinary hospitals and pharmacies.
Key Players: Vetraise Remedies, Pet Meds, Mars Petcare, Norway Veterinary Hospital, etc.
Patient Support and Services
This can be fostered by broader veterinary consultation and diagnosis, treatment protocol, exercise restriction, preventive medication, and post-treatment care.
Key Players: Boehringer Ingelheim, Elanco Animal Health, Merial, etc.
Latest Announcements by Industry Leaders
- In August 2025, Inspire Veterinary Partners, Inc., an owner and provider of pet health care services throughout the U.S., announced it had signed an exclusive, non-binding Letter of Intent to acquire a New Jersey-based animal hospital. Kimball Carr, Inspire President and Chief Executive Officer, said that this shows they are a unique operator of veterinary practices, which is working with teams and sellers of clinics.
- In May 2025, A team of researchers at Texas A&M University and the University of Georgia (UGA) announced that they had received more than $4 million from federal and non-governmental organizations to boost research on Chagas disease prevalence, diagnostics, and treatment to benefit both dogs and humans. Dr. Sarah Hamer, a professor at Texas A&M College, commented that this will advance Chagas disease research to understand the process of natural infections, disease, and the effect of treatments.
What are the Recent Developments in the Heartworm Treatment Products Market?
- In August 2025, Krka UK launched Pet Shield, a new umbrella brand that integrates its trusted flea and worming products under one clear, customer-focused identity.
- In July 2025, Sam’s Club unveiled pharmacy and healthcare services to customers, including same-day delivery of pharmaceutical products to members and non-members via the DoorDash Drive white label fulfillment platform.
- In April 2024, Boehringer Ingelheim, a global player in animal health, introduced NexGard SPECTRA® (afoxolaner and milbemycin oxime) in India, following its approval by the Central Drugs Standard Control Organisation (CDSCO).
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
